ライフサイエンスコーパス: MDR-TB

1 MDR TB regimens including more potentially effective dru

2 MDR-TB appears not to cause infection or disease more re

3 MDR-TB isolates were not identified in the isolates from

4 MDR-TB was defined as culture-confirmed TB disease with

5 , we retrospectively reviewed records of 127 MDR TB patients with and without MB testing between 2004

6 ulation per year (95% SI: 198, 269) with 14% MDR-TB.

7 Of 152 MDR-TB patients, 72 (47%) were from prior to and 80 (53%

8 From 278 MDR-TB/RR-TB index case households, 743 HHCs were enroll

9 tober 2015 to April 2016, 1016 HHCs from 284 MDR-TB cases were enrolled.

10 tion interval (S.I.) 8.9-24.4%), avert 7,721 MDR-TB cases (14.1% reduction, 95% S.I. 5.3-23.8%), and

11 For example, by 2040, we projected absolute MDR-TB incidence to account for 5% (IQR: 4-9%) of incide

12 seloads, which increase the risk of acquired MDR-TB.

13 sting practice but required 2,500 additional MDR-TB treatments and 60 four-module GeneXpert systems a

14 e conducted a cross-sectional study of adult MDR-TB cases and their HHCs in 8 countries with high TB

15 f 20 mo (interquartile range 16-23 mo) after MDR TB treatment initiation.

16 e compounds showed improved activity against MDR-TB while retaining low toxicity with higher microsom

17 clades, which underly 64.2% and 94.0% of all MDR-TB and XDR-TB isolates, respectively.

18 ations, the test can detect about 60% of all MDR-TB cases.

19 m a previous, population-based study, to all MDR-TB patients reported to the National TB Surveillance

20 Among MDR-TB cases, 27% (95%CI:10-44) in the before period con

21 ity was higher among XDR-TB cases than among MDR-TB cases (PR, 1.82; 95% CI, 1.10-3.02) and drug-susc

22 ent program provides ideal conditions for an MDR-TB and XDR-TB epidemic of unparalleled magnitude.

23 Twenty-one patients either had an MDR-TB risk factor and a smear-positive sputum specimen,

24 7 patients with pulmonary MDR-TB occupied an MDR-TB ward in South Africa and wore face masks on alter

25 Once an MDR-TB diagnosis is established, additional testing is w

26 action indicated that catastrophic costs and MDR TB were associated with similar proportions of adver

27 In the new smear-negative and MDR TB cascades, a substantial proportion of patients wh

28 e of care, especially for smear-negative and MDR TB patients.

29 Retreatment smear-positive and MDR TB patients had poorer treatment outcomes than the g

30 rall TB prevalence (from 2.78% to 2.31%) and MDR-TB prevalence (from 0.74% to 0.63%), and cost US$543

31 95% uncertainty range [UR]: -1.4%, 1.7%) and MDR-TB incidence by 2.4% (95% UR: -5.2%, 9.1%) relative

32 istance was found in 3/215 (1.4%) cases, and MDR-TB was found in 8/223 (3.6%) cases.

33 cant increases in costs for treating HIV and MDR-TB.

34 eillance data suggest that HIV infection and MDR-TB may converge in several countries.

35 a evaluating links between HIV infection and MDR-TB to quantify convergence of these 2 epidemics, eva

36 d replication of clinically-isolated MTB and MDR-TB strains.

37 In the case of INH, EMB, PZA and MDR-TB, DeepAMR achieved its best mean sensitivity of 94

38 specimen in 159 (89.8%) of 177 specimens and MDR-TB in 109 (95.6%) of 114 specimens compared to conve

39 important tool for rapid detection of TB and MDR-TB globally.

40 important tool for rapid detection of TB and MDR-TB globally.

41 h sputum PCR most effectively reduces TB and MDR-TB prevalence, doing so cost-effectively.

42 lity-adjusted life years (QALYs), and TB and MDR-TB prevalence.

43 D as a new and effective drug against TB and MDR-TB.

44 types involved in community transmission and MDR-TB respectively.

45 tcomes for drug-susceptible tuberculosis and MDR-TB.

46 in the proportion of new cases identified as MDR-TB; though time to MDR treatment was reduced, it was

47 improve patients' health, protect background MDR TB drugs, and decrease transmission, but would likel

48 retreatment cases, 12 (16%) were infected by MDR-TB.

49 31 (TCG/TTG) and katG 315 (AGC/ACC)] causing MDR-TB and verification of loss of the respective wild t

50 ) and repurposed (linezolid and clofazimine) MDR-TB drugs and the new shorter MDR-TB regimen in child

51 require KatG activation is crucial to combat MDR TB.

52 ment outcomes of microbiologically confirmed MDR-TB.

53 d suggest measures necessary for controlling MDR-TB and XDR-TB in this context.

54 Compared with conventional MDR-TB treatment, implementing the shorter regimen would

55 use of a molecular diagnostic test to detect MDR-TB improves clinical outcomes.

56 ay and conventional DST results in detecting MDR-TB (kappa = 0.95, p<0.01).

57 (SNPs), whereas reinfection with a different MDR-TB strain was assumed where the distance was 10 or m

58 2%]) and thus had an opportunity for earlier MDR-TB diagnosis with PSQ on sediment.

59 itiation of shorter, safer, highly effective MDR-TB regimens; and treatment adherence support are cri

60 y more likely to be hospitalized with either MDR-TB or XDR-TB than were non-health care workers.

61 The estimated MDR-TB incidence reduction was 90% (9%-99%) using data f

62 39 [2.5%]) were identified as having evolved MDR-TB de novo and 6 as having been reinfected with a di

63 Data on patients started on bedaquiline for MDR TB between September 2012 and August 2016 were colle

64 Data on patients started on bedaquiline for MDR TB between September 2012 and August 2016 were colle

65 ly 6 mo of costs-specific follow-up data for MDR TB patients.

66 ity, as well as changing recommendations for MDR TB treatment.

67 ervational study of 1,659 adults treated for MDR TB during 2005-2010 in nine countries: Estonia, Latv

68 including the Hain V2 and Nipro assays, for MDR-TB detection.

69 Culture conversion for MDR-TB patients improved after introduction of MTBDRplus

70 culture conversion, 183 days vs 93 days for MDR-TB; P < .001).

71 phases, and the role of injectable drugs for MDR-TB.

72 nsistently lower transmission efficiency for MDR-TB than for DS-TB; equal transmission efficiency; an

73 Somalia with MDR-TB and the implications for MDR-TB programs in East Africa.

74 of Rifampicin-resistant (RR) TB, a proxy for MDR-TB, and the treatment outcomes with standard and sho

75 endations, an effective all-oral regimen for MDR-TB can be assembled.

76 gy tool for building a treatment regimen for MDR-TB is also provided.Conclusions: New recommendations

77 Long aggressive regimens for MDR-TB treatment are associated with lower risk of disea

78 rently used in children in many settings for MDR-TB treatment, lower doses may approximate current ad

79 This rapid diagnostic test for MDR-TB can therefore be reliably implemented in a resour

80 evelop a rapid molecular diagnostic test for MDR-TB.

81 Children routinely treated for MDR-TB in 2 observational studies (2011-2015, 2016-2018)

82 s for clinically diagnosed cases treated for MDR-TB.

83 al dose of linezolid in children treated for MDR-TB.

84 e (9/36 [25%]); or did not have PSQ used for MDR-TB diagnosis (12/38 [32%]) and thus had an opportuni

85 ll fluoroquinolone mutations identified from MDR-TB patient sputum samples, as confirmed by DNA seque

86 that could differentiate NTM infection from MDR-TB; however, the most common lesion location in NTM

87 s having disease recurrence if cultures grew MDR-TB or they re-initiated MDR-TB therapy.

88 Patients were divided into two groups (MDR-TB and XDR-TB) based on two types of drug resistance

89 tive for TB during screening, 11 (2.04%) had MDR-TB, 147 (27.32%) had drug-sensitive TB, and 380 (70.

90 h drug susceptibility testing, 82 (1.7%) had MDR-TB.

91 ture uncertainty, specific responses to halt MDR-TB transmission should be prioritized.

92 Having MDR TB was associated with a higher likelihood of incurr

93 52 samples from patients suspected of having MDR-TB were included in the study.

94 s from patients in India suspected of having MDR-TB.

95 isolates of TB patients suspected of having MDR-TB.

96 lecting for rifampicin resistance, and hence MDR-TB.

97 to detection of MDR-TB in an area with high MDR-TB prevalence.

98 eta-analysis of observational data, improved MDR-TB treatment success and survival were associated wi

99 ence and may be contributing to increases in MDR-TB prevalence.

100 Many crucial management issues in MDR-TB treatment remain unanswered.

101 one, but produced only a modest reduction in MDR-TB prevalence (from 0.74% to 0.69%) and had minimal

102 if cultures grew MDR-TB or they re-initiated MDR-TB therapy.

103 ohort study of adult patients that initiated MDR-TB treatment with individualized regimens between Se

104 rior to hospital discharge in a high HIV/low MDR TB prevalence setting.

105 -26%) in Vietnam assuming consistently lower MDR-TB transmission efficiency, versus 15% (IQR: 8-27%)a

106 We evaluated the accuracy of the BD MAX MDR-TB assay (BD MAX) in South Africa, Uganda, India, an

107 The BD MAX MDR-TB assay had high sensitivity and specificity for de

108 The BD MAX MDR-TB assay had high sensitivity and specificity for de

109 In the before period, measured MDR-TB prevalence among new cases was 0.7% (95% CI1.4-3.

110 , 35% remained smear positive after a median MDR-TB treatment duration of 8.8 weeks.

111 4/114 (74%) of patients on 9- vs 20/24-month MDR-TB regimens, respectively (P = .06).

112 CDC offers rapid confirmation of MDR TB by the molecular detection of drug resistance (MD

113 ts should be considered for the diagnosis of MDR TB.

114 nsatory evolution in the global epidemics of MDR TB.

115 ) life expectancy from time of initiation of MDR TB treatment at age 30 was 36.0 y (33.5, 38.7) assum

116 Overdiagnosis of MDR TB may result in treatment with second-line drugs th

117 18% (95% CI = 6.9%-28%), similar to that of MDR TB (20% [95% CI = 14%-25%]).

118 duced the time to detection and treatment of MDR TB.

119 n, 95% S.I. 5.3-23.8%), and prevent 46.6% of MDR-TB deaths (95% S.I. 32.6-56.0%) in South Africa over

120 At diagnosis, 69% of MDR-TB cases were positive for acid-fast bacilli sputum

121 (95% SI: 246, 558), with 46% being cases of MDR-TB, while incorporating programmatic management of M

122 ately 30 years ago was an important cause of MDR-TB in Bamako.

123 Chest X-ray lesion characteristics of MDR-TB show significant correlation among cavities, nodu

124 d significantly reduced time to detection of MDR-TB in an area with high MDR-TB prevalence.

125 The time to detection of MDR-TB was significantly less using the MTBDRplus assay

126 h sputum PCR reserved for rapid detection of MDR-TB.

127 pre-MDR-TB to prevent further development of MDR-TB.

128 isoniazid and rifampicin in the diagnosis of MDR-TB, has good diagnostic accuracy, but its impact on

129 al deficit in the transmission efficiency of MDR-TB that closes over time.

130 bout the relative transmission efficiency of MDR-TB.

131 tly on the future transmission efficiency of MDR-TB.

132 A successful response to the emergence of MDR-TB and XDR-TB will necessitate increased resources f

133 tly needed to avert the de novo emergence of MDR-TB during treatment.

134 is drug pipeline and widespread emergence of MDR-TB signal an urgent need for more innovative interve

135 De novo emergence of MDR-TB was assumed where the genomic distance was 5 or f

136 lic health threat, but accurate estimates of MDR-TB burden among children are lacking.

137 he computed tomography (CT) scan findings of MDR-TB and XDR-TB patients.

138 In this cross-sectional study of HHCs of MDR-TB and rifampicin-resistant tuberculosis (RR-TB) ind

139 The high percentage of HHCs of MDR-TB/RR-TB index cases willing to take hypothetical MD

140 Estimated incidence of MDR-TB hospitalization was 64.8 per 100,000 health care

141 The incidence of MDR-TB was projected to expand in most scenarios, but th

142 We found the incidence of MDR-TB with acquired FQN resistance would also be lower

143 vings and in reduced mortality, incidence of MDR-TB, and incidence of acquired FQN-resistant disease

144 in health system savings, lower incidence of MDR-TB, and lower mortality than no treatment.

145 Outcomes modeled were the incidence of MDR-TB, MDR-TB with FQN resistance, TB-related death, qu

146 Total RIF resistance indicative of MDR-TB in treatment-naive patients was 5.52%, far exceed

147 ents including reduced time to initiation of MDR-TB treatment, culture conversion, and improved infec

148 approach, we estimated that the majority of MDR-TB was due to the recent transmission of already-res

149 Good practices in the management of MDR-TB are described.

150 ile incorporating programmatic management of MDR-TB into these programs reduced incidence to 233 case

151 incorporation of programmatic management of MDR-TB is vital if control is to be achieved.

152 Institutional outbreaks of MDR-TB have primarily affected HIV-infected persons.

153 osis (p = 0.010), with the best predictor of MDR-TB lesions being the presence of a nodule.

154 rtmental model to project the progression of MDR-TB epidemics in South Africa and Vietnam under alter

155 ant TB, de novo emergence and reinfection of MDR-TB strains equally contributed to MDR development.

156 The sensitivity and specificity of MDR-TB were 81.8% and 99.0% in new cases and 77.8% and 9

157 nt, thereby helping to control the spread of MDR-TB in the community.

158 ion of FQ-resistant mutations at the time of MDR-TB diagnosis.

159 vided on the role of surgery in treatment of MDR-TB and for treatment of contacts exposed to MDR-TB a

160 re is limited evidence on the willingness of MDR-TB HHCs to take MDR-TB preventive therapy (MDR TPT)

161 r smear-positive TB had reasonable impact on MDR-TB incidence, but at substantial price and little im

162 r related Beijing isolates that included one MDR-TB isolate.

163 mized trials are urgently needed to optimize MDR-TB treatment.

164 tive and 41 with isoniazid mono-resistant or MDR TB, were enrolled at one site in South Africa.

165 tant and extremely drug resistant organisms (MDR-TB and XDR-TB).

166 drug-resistance testing, and an overburdened MDR-TB treatment program provides ideal conditions for a

167 ld substantially reduce TB, and particularly MDR-TB, mortality.

168 Most pediatric MDR-TB cases were female (n = 51 [62%]), median age was

169 Better estimates of pediatric MDR-TB burden in the United States are needed and should

170 ere was 42%-55% underestimation of pediatric MDR-TB cases when using only culture-confirmed case defi

171 rtain potential underestimation of pediatric MDR-TB, we surveyed high-burden states for clinically di

172 This review fills a gap in the pediatric MDR-TB literature by providing practice-based recommenda

173 sulting in underestimation of true pediatric MDR-TB burden in the United States using strictly bacter

174 able targeted treatment of patients with pre-MDR-TB to prevent further development of MDR-TB.

175 f the effectiveness of therapy in preventing MDR-TB was as low as 10%.

176 ng patients with culture-confirmed pulmonary MDR-TB.

177 Over 3 months, 17 patients with pulmonary MDR-TB occupied an MDR-TB ward in South Africa and wore

178 ne, and the addition of sputum PCR for rapid MDR-TB detection may be cost-saving over time.

179 ed PZA resistance mutations in 88 recultured MDR-TB isolates from an archived series collected in 200

180 Of 586 reported MDR-TB cases, 10% (59) were eligible for the shorter reg

181 ave limited access to the new and repurposed MDR-TB drugs.

182 r, no recommendation was given for the short MDR-TB regimen.

183 lofazimine) MDR-TB drugs and the new shorter MDR-TB regimen in children and adolescents.

184 r the use of these drugs and for the shorter MDR-TB regimen in the pediatric population.

185 ay reduce long-term treatment costs and slow MDR-TB transmission.

186 en would have reduced the US annual societal MDR-TB cost burden by 4%, but the cost burden for eligib

187 Some MDR-TB isolates had near identical genomic variation, pr

188 ce on the willingness of MDR-TB HHCs to take MDR-TB preventive therapy (MDR TPT) to decrease their ri

189 and the emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) strai

190 and the emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) strai

191 yrazinamide (PZA)], multi-drug resistant TB (MDR-TB) and pan-susceptible TB (PANS-TB: MTB that is sus

192 uberculosis (TB) and multidrug-resistant TB (MDR-TB) are major health problems in Western Province, P

193 on the treatment of multidrug-resistant TB (MDR-TB) as well as isoniazid-resistant but rifampin-susc

194 an increased risk of multidrug-resistant TB (MDR-TB) emerging (8%), compared to drug-sensitive TB (0.

195 HIV or high risk of multidrug-resistant TB (MDR-TB) in the public sector, population-level impact ma

196 suspected of having multidrug-resistant TB (MDR-TB) or HIV-associated TB, and many countries are mov

197 Multidrug-resistant TB (MDR-TB) was significantly associated with quinolone resi

198 berculosis (TB) and multi-drug resistant TB (MDR-TB), repurposing FDA (U.S. Food and Drug Administrat

199 e novo emergence of multi-drug-resistant TB (MDR-TB).

200 emerging threat from multidrug resistant TB (MDR-TB).

201 orn by patients with multidrug-resistant TB (MDR-TB).

202 -course regimens for multidrug-resistant TB (MDR-TB).

203 tcomes modeled were the incidence of MDR-TB, MDR-TB with FQN resistance, TB-related death, quality-ad

204 The MDR-TB assay appears to be a rapid and accurate method f

205 istically significant difference between the MDR-TB and XDR-TB groups (p > 0.05).

206 We evaluated the MDR-TB (multidrug-resistant tuberculosis) assay, which u

207 MTBC resistance profiles from the MDR-TB assay were compared to results with the agar prop

208 luded fewer and more nodules of 10 mm in the MDR-TB and XDR-TB groups, respectively.

209 Due to the prevalence of the MDR-TB and extensively drug resistant tuberculosis (XDR-

210 ues may contribute to the convergence of the MDR-TB and HIV infection epidemics.

211 The performance of the MDR-TB assay was compared to identification using nuclei

212 r the detection of drug resistance using the MDR-TB assay were 100% and 92.3% for rifampin, 100% and

213 they were on >/=1 medication to which their MDR-TB strain was likely susceptible.

214 proportion of incident cases attributable to MDR-TB increased from 16% to 35%.

215 PSQ, median time from specimen collection to MDR-TB treatment initiation was 12 days vs 51 days when

216 -TB and for treatment of contacts exposed to MDR-TB and treatment of isoniazid-resistant TB.

217 ffectiveness in prevention of progression to MDR-TB, and confirmed cost-effectiveness.

218 The lesion locations related to MDR-TB were the upper right and left lung (p = 0.00).

219 Time to MDR-TB treatment initiation, culture conversion, and inf

220 e important bactericidal drugs used to treat MDR TB, and resistance to one or both of these drugs is

221 number, and duration of drugs used to treat MDR-TB.

222 Costs for treating MDR-TB are also expected to rise significantly with Xper

223 ene Bell Foundation's experience of treating MDR-TB in North Korea.

224 r treating multidrug-resistant tuberculosis (MDR TB), the World Health Organization (WHO) recommends

225 at detects multidrug-resistant tuberculosis (MDR TB), we retrospectively reviewed records of 127 MDR

226 herapy for multidrug-resistant tuberculosis (MDR TB).

227 eatment of multidrug-resistant tuberculosis (MDR TB).

228 r treating multidrug-resistant tuberculosis (MDR TB); however, there is limited data guiding their us

229 tidrug-resistant Mycobacterium tuberculosis (MDR-TB) accounts for 3.7% of new cases of TB annually wo

230 tidrug-resistant Mycobacterium tuberculosis (MDR-TB) strains making its control difficult.

231 and extensively drug-resistant tuberculosis (MDR-TB and XDR-TB, respectively) has intensified the cri

232 h rates of multidrug-resistant tuberculosis (MDR-TB) and are thought to drive general population tube

233 spread of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR

234 ristics of multidrug-resistant tuberculosis (MDR-TB) and non-tuberculous mycobacteria (NTM) infection

235 ely 50% of multidrug-resistant tuberculosis (MDR-TB) and over 90% of extensively drug-resistant tuber

236 duals with multidrug-resistant tuberculosis (MDR-TB) are at high risk of infection and subsequent dis

237 ated with multi-drug resistant tuberculosis (MDR-TB) are of major concern.

238 e assessed multidrug-resistant tuberculosis (MDR-TB) cases and their household contacts (HHCs) to inf

239 en develop multidrug-resistant tuberculosis (MDR-TB) each year.

240 detecting multidrug-resistant tuberculosis (MDR-TB) in comparison with standard drug susceptibility

241 pulmonary multidrug-resistant tuberculosis (MDR-TB) in Tomsk, Russia.

242 Multidrug-resistant tuberculosis (MDR-TB) is an important global public health threat, but

243 Multi-drug-resistant tuberculosis (MDR-TB) is an increasing public health threat, and promp

244 istance in multidrug-resistant tuberculosis (MDR-TB) is common and it is not clear how it affects int

245 duals with multidrug-resistant tuberculosis (MDR-TB) is controversial.

246 eatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic, expensive, and has generally

247 Whether multidrug-resistant tuberculosis (MDR-TB) is less transmissible than drug-susceptible (DS-

248 Multi-drug-resistant tuberculosis (MDR-TB) is simultaneously resistant to isoniazid and rif

249 Multidrug-resistant tuberculosis (MDR-TB) jeopardizes global TB control.

250 han 30% of multidrug-resistant tuberculosis (MDR-TB) patients are currently diagnosed, due to laborat

251 eatment of multidrug-resistant tuberculosis (MDR-TB) patients.

252 Multidrug-resistant tuberculosis (MDR-TB) poses a serious threat to global public health.

253 Globally, multidrug resistant tuberculosis (MDR-TB) remains underdiagnosed.

254 nefit from multidrug-resistant tuberculosis (MDR-TB) screening, all nucleic acid amplification test (

255 -12 month) multidrug-resistant tuberculosis (MDR-TB) treatment regimen (as compared to the convention

256 ortant for multidrug-resistant tuberculosis (MDR-TB) treatment.

257 eatment of multidrug-resistant tuberculosis (MDR-TB) with long regimens.

258 Multidrug-resistant tuberculosis (MDR-TB), caused by drug-resistant strains of Mycobacteri

259 tection of multidrug-resistant tuberculosis (MDR-TB), in Rwanda.

260 including multidrug-resistant tuberculosis (MDR-TB), is a major global health problem.

261 tection of multidrug-resistant tuberculosis (MDR-TB), obtaining a diagnostic accuracy of more than 97

262 ients with multidrug-resistant tuberculosis (MDR-TB).

263 to detect multidrug-resistant tuberculosis (MDR-TB).

264 agement of multidrug-resistant tuberculosis (MDR-TB).

265 r treating multidrug-resistant tuberculosis (MDR-TB); however, there are limited data guiding their u

266 eligibility for the shorter regimen among US MDR-TB cases that had full drug susceptibility testing (

267 DST use, our analysis found a minority of US MDR-TB patients would have been eligible for the shorter

268 Where MDR-TB was diagnosed, WGS was used to determine the geno

269 We seek to explore possible causes why MDR-TB has been found to occur much more often in patien

270 se outcome was independently associated with MDR TB (odds ratio [OR] = 8.4 [95% CI = 4.7-15], p<0.001

271 tive observational study among patients with MDR TB in Georgia receiving a bedaquiline or delamanid-b

272 .0 y (33.5, 38.7) assuming all patients with MDR TB received bedaquiline, 35.1 y (34.4, 35.8) assumin

273 Among 156 patients with MDR TB, 100 were enrolled and 95 were receiving a bedaqu

274 Among patients with MDR TB, bedaquiline-based regimens were associated with

275 g bedaquiline available to all patients with MDR TB, restricting bedaquiline usage to patients with M

276 ding bedaquiline access to all patients with MDR TB.

277 roved response to treatment in patients with MDR TB.

278 es, 7 had a positive MTBDRplus assay (3 with MDR-TB).

279 low in Harris County and is associated with MDR-TB.

280 However, among children with MDR-TB, there are no linezolid pharmacokinetic data, and

281 Compared with MDR-TB cases, XDR-TB cases were more likely to have diss

282 e radiographic findings that correlated with MDR-TB were infiltrates (p = 0.010), cavities (p = 0.021

283 cohort study for all patients diagnosed with MDR-TB in Sweden 1992-2014.

284 e transmission potential of individuals with MDR-TB may vary by infectiousness, frequency of contact,

285 TB infection in contacts of individuals with MDR-TB.

286 XDR-TB are similar to those of patients with MDR-TB for cavitary, parenchymal, and non-parenchymal lu

287 e data were provided for 9,153 patients with MDR-TB from 32 observational studies.

288 HIV-infected patients with MDR-TB have unacceptably high mortality; both antiretrov

289 ive, observational study among patients with MDR-TB in Georgia who were receiving a bedaquiline- or d

290 Patients with MDR-TB initiated effective treatment 5 weeks earlier whe

291 Surgical face masks on patients with MDR-TB significantly reduced transmission and offer an a

292 Among 156 patients with MDR-TB, 100 were enrolled and 95 were receiving a bedaqu

293 Of 157 patients with MDR-TB, 56.1% (n=88) had PZA resistant strains and 49.7%

294 Among patients with MDR-TB, bedaquiline-based regimens were associated with

295 In patients with MDR-TB, gDST PZA resistance was associated with a longer

296 (SCC) and treatment outcome in patients with MDR-TB.

297 border movement of people from Somalia with MDR-TB and the implications for MDR-TB programs in East

298 During treatment of a subject with MDR-TB, serial computed tomography (CT) scans showed thi

299 istics overlap between XDR-TB and those with MDR-TB.

300 re workers than non-health care workers with MDR-TB or XDR-TB were women (78% vs. 47%; P < 0.001), an